Palliative treatment of metastatic bone pain with radiopharmaceuticals: A perspective beyond Strontium-89 and Samarium-153

Liberal, Francisco; Tavares, Adriana; Tavares, João Manuel R. S.

doi:10.1016/j.apradiso.2016.01.003

Cited by 47 publications

(26 citation statements)

References 69 publications

(126 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In consideration of the logistical limitations of the use of 11C-Ch, Ch was subsequently labeled with 18F, which, thanks to the increased half-life (109.8 min), allows storage and transport. However, 18F-Ch radiotracer is characterized by an increased urinary excretion compared to 11C-Ch [9].…”

Section: Main Text 21 Prostate Cancermentioning

confidence: 99%

“…Skeletalrelated events can reduce the health-related quality of life secondary to debilitating pain, paralysis, loss of mobility, and hospitalization. Systemic palliative-targeted therapy with suitable radiopharmaceuticals has emerged as a particularly appealing and efficient treatment modality for patients with multiple skeletal metastases [9].…”

Section: Main Text 21 Prostate Cancermentioning

confidence: 99%

“…However, high-energy β − particles, with a range of several millimeters in tissues, can irradiate cells nearby the targeted tumor. Conversely, α particles (typical penetration range of <100 μm) and Auger electrons (penetration range of several nanometers to micrometers) have shorter penetration ranges and higher linear energy transfer (LET) [9].…”

Section: Main Text 21 Prostate Cancermentioning

confidence: 99%

See 2 more Smart Citations

Samarium-153 Therapy and Radiation Dose for Prostate Cancer

Parlak¹,

Gümüşer²,

Sayıt³

2016

Prostate Cancer - Leading-Edge Diagnostic Procedures and Treatments

View full text Add to dashboard Cite

Prostate cancer (PC) is one of the most frequent malignancies in Western countries. At initial diagnosis, bone metastases are present in 15-30% of cases. These metastases cause some complications including bone fracture, hypercalcemia, and bone pain, which significantly affect patients' quality of life. Radionuclide treatment was created as an alternative to external palliative radiotherapy in the treatment of bone pain arising from bone metastasis of PC. The basic principle of the radionuclide treatment of pain is that the uptake of radioactive material is kept in a high amount that is enough to constitute a proper clinical impact in the tumor, and it is kept at a low dose enough to avoid the occurrence of significant adverse effects in other organs (commonly in the bone marrow). Samarium-153 ethylenediaminetetramethylenephosphonic acid (153Sm-EDTMP) is a radiopharmaceutical compound that has an affinity for skeletal tissue and concentrates in areas of increased bone turnover, localizes in the skeleton, and is excreted via glomerular filtration. Medical staff preparing and administering radiopharmaceuticals in nuclear medicine, whether for diagnostic imaging or for therapeutic application, may receive significant radiation doses to their hands, particularly the fingers. Sm-153 treatment can be used as an effective and safe treatment alternative in the management of metastatic bone pain. Radiation protection of the public and the environment after Sm-153 EDTMP therapy is important.

show abstract

Section: Main Text 21 Prostate Cancermentioning

confidence: 99%

Section: Main Text 21 Prostate Cancermentioning

confidence: 99%

Section: Main Text 21 Prostate Cancermentioning

confidence: 99%

See 1 more Smart Citation

Samarium-153 Therapy and Radiation Dose for Prostate Cancer

Parlak¹,

Gümüşer²,

Sayıt³

2016

Prostate Cancer - Leading-Edge Diagnostic Procedures and Treatments

View full text Add to dashboard Cite

show abstract

“…Lutetium-177 EDTMP is one of the recent entrants to the list of clinically useful bone pain-palliating agents. [ 9 ] A recent review[ 10 ] on bone pain-palliating agents provides an excellent perspective beyond strontium-89 and samarium-153. In another review, a comparative evaluation was made between surface bone-seeking radiopharmaceuticals, namely rhenium-186 HEDP, rhenium-188 HEDP, samarium-153 EDTMP, and the volume-seeker strontium-89 for the treatment of skeletal metastases.…”

Section: Introductionmentioning

confidence: 99%

Rhenium-188 hydroxyethane 1,1-diphosphonic acid (HEDP) for bone pain palliation using BARC-HEDP kits versus Pars-HEDP kits: A comparison on preparation and performance aspects at hospital radiopharmacy

et al. 2018

View full text Add to dashboard Cite

Purpose of the Study:Rhenium-188 hydroxyethane 1,1-diphosphonic acid (HEDP) is a clinically established radiopharmaceutical for palliation of bone pain due to osseous metastases. Recently, the Bhabha Atomic Research Centre (BARC) had developed a freeze-dried kit for the preparation of rhenium-188 HEDP. The present study compares the radiochemistry aspects of indigenous BARC-HEDP kits with commercially available HEDP kits from Pars Isotope Company, Iran.Materials and Methods:Freeze-dried HEDP kits were obtained from Radiopharmaceuticals Division, BARC, and Pars Isotope Company, Iran. Following recommended procedures, rhenium-188 HEDP was prepared using freeze-dried kits from both sources using freshly eluted rhenium-188 sodium perrhenate obtained from a commercial tungsten-188/rhenium-188 generator.Results:Both kits could be used for the preparation of rhenium-188 HEDP in >95% radiochemical purity (RCP). Rhenium-188 HEDP prepared from both kits showed comparable in vitro stability as well as pharmacokinetic properties. The normal bone-to-soft tissue ratio observed for rhenium-188 HEDP prepared using BARC-HEDP kit and Pars-HEDP kit was 1.993 and 1.416, respectively.Conclusions:Both HEDP kits provided a user-friendly solution for the preparation of rhenium-188 HEDP. While Pars-HEDP-kit permits the addition of only 2 mL of rhenium-188 perrhenate solution per kit vial, BARC-HEDP-kit allows up to 5 mL. This feature permits the preparation of patient dose of rhenium-188 HEDP even with older generators providing rhenium-188 perrhenate having a low radioactive concentration (activity/mL). In addition, availability of an indigenous product is always preferable over imported options.

show abstract

“…In fact, radiopharmaceuticals act both volumetrically and superficially on bone and, mostly for short-range particles, they must reach the nucleus of the cell where they can interact with DNA and exert their killing action. Regarding this, Guerra Liberal et al underlined that 223 Ra alpha particles seemed an optimal strategy for the treatment of bone micrometastases (63). Is micrometastatic disease the only setting for the usefulness for the short range of action of 223 Ra?…”

Section: Mechanism Of Actionmentioning

confidence: 99%

Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer

Buroni

Persico

Pasi

et al. 2016

View full text Add to dashboard Cite

Abstract. 223 Prostate cancer (PCa) is the most common malignancy in men (1). In patients affected by advanced PCa, defined as hormonesensitive disease since the tumor still requires androgen for growth, androgen deprivation therapy (ADT), including luteinizing hormone-releasing hormone (LHRH) agonists, antagonists and anti-androgens, represents the first-line treatment. Unfortunately some cancer cells develop resistance to ADT, indicating the progression of the disease to metastatic castration-resistant prostate cancer (mCRPCa). Such resistance to castration occurs in most patients (2) and, despite the approval of new therapeutic agents, mCRPCa remains a lethal disease (3). Nowadays the new therapeutic landscape for patients affected by mCRPCa aims to extend overall survival (OS) and includes cytotoxic, new-generation anti-androgens, immunotherapeutics and radiopharmaceuticals (4, 5).Bones are the preferred site of metastasis. Almost 90% of men who die from PCa have bone-metastatic disease (6), with a 5-year OS rate of 20%. Due to the fragility of bone with metastases, with the related risk of pain, fractures, spinal cord compression and hematological consequences, several drugs have been developed to treat the osseous involvement of this disease. In previous years, the optimal treatment aimed to relieve pain and reduce skeletal morbidity.Besides systemic therapies, bone-targeted agents that focus their activity on bone, such as bisphosphonates, monoclonal antibody and radiopharmaceuticals, have become available. The bisphosphonate zoledronic acid, the antibody to receptor activator of nuclear factor kappa-B ligand (RANKL) denosumab and radiopharmaceuticals [such as 89 Sr and 153 Sm-ethylene diamine tetramethylene phosphonate ( 153 Sm-EDTMP)], were approved for delaying skeletal-related events (SREs) and for the palliation of bone pain from mCRPCa. Radionuclide TherapyRadionuclide therapy is known to deliver ionizing radiation to tumor sites, thereby killing cancer cells (7). Bone-targeted radiopharmaceuticals localize their radiation to sites of high bone remodeling. 5719

show abstract

Palliative treatment of metastatic bone pain with radiopharmaceuticals: A perspective beyond Strontium-89 and Samarium-153

Cited by 47 publications

References 69 publications

Samarium-153 Therapy and Radiation Dose for Prostate Cancer

Samarium-153 Therapy and Radiation Dose for Prostate Cancer

Rhenium-188 hydroxyethane 1,1-diphosphonic acid (HEDP) for bone pain palliation using BARC-HEDP kits versus Pars-HEDP kits: A comparison on preparation and performance aspects at hospital radiopharmacy

Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer

Contact Info

Product

Resources

About